Accessibility Menu
Atossa Therapeutics logo

Atossa Therapeutics(NASDAQ) ATOS

Current Price$2.34
Market Cap$24.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-96%
1 Year-82%
1 Month+27%
Atossa Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.412026-07-23
Atossa Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.84%USD 2.392026-07-16
1 month+26.84%USD 1.902026-06-23
3 month-57.72%USD 5.702026-04-24
Year to date-72.77%USD 8.852025-12-31
1 year-81.87%USD 13.302025-07-23
3 year-85.26%USD 16.352023-07-24
5 year-96.16%USD 62.702021-07-23
Since inception-99.98%USD 12,960.012012-11-08

Atossa Therapeutics Financials at a Glance

Market Cap

$24.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$37.64M

EPS (TTM)

-$4.37

P/E Ratio

-0.55

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$2.34

Volume

7

Open

$2.35

Previous Close

$2.41

Daily Range

$2.34 - $2.35

52-Week Range

$1.70 - $19.35

Estimated Earnings Date

Aug 11, 2026

ATOS News

smart-doctor-contemplating-your-question-getty

Can Atossa Therapeutics Stock Keep Climbing?

Cory RenauerJun 28, 2021
Scientist in lab looking through microscope

Why Atossa Therapeutics Stock Is Jumping Today

Keith SpeightsJun 22, 2021
Breast cancer pink ribbon

Why Atossa Therapeutics Stock Is Tumbling Today

Keith SpeightsJun 9, 2021
A researcher studying a sample in a petri dish

Why Atossa Therapeutics Blasted 30% Higher on Monday

Eric VolkmanJun 7, 2021
Cancer attacking an organism

Why Atossa Therapeutics Soared 20% Higher Today

Eric VolkmanJun 1, 2021
Growth-GettyImages-497392002

Why Atossa Therapeutics Stock Soared Today

Joe TenebrusoFeb 4, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Atossa Therapeutics

Atossa develops medicines for breast cancer and rare diseases. Its main drug aims to help women with breast cancer. The company focuses on treatments that may improve patient outcomes.

Products and Services

  • Oral (Z)-endoxifen: Lead drug in clinical trials for breast cancer; no revenue generated.
  • Rare Disease Programs: Early-stage research for Duchenne Muscular Dystrophy and McCune-Albright Syndrome; no commercial sales.
  • Immunotherapy Initiatives: Preclinical work on cell-based cancer therapies; not yet in market.

Growth and Expansion

  • Expanded clinical trials for (Z)-endoxifen in breast cancer from 2023 to 2025.
  • Entered rare disease research for Duchenne Muscular Dystrophy in 2025 and began preparation for McCune-Albright Syndrome research, with intent to seek formal designation in 2026.
  • Signed At the Market Offering Agreement in February 2026 for up to $50 million in equity sales.
  • Established proprietary manufacturing process for (Z)-endoxifen by 2025.

What Makes Atossa Stand Out

Atossa holds patents for its main drug, protecting its research until 2038. The company targets breast cancer types that resist standard treatments. It relies on partnerships and third-party providers for manufacturing and clinical trials.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $34.8 million in 2025, up 36% from 2024.
  • Operating expenses rose 34.4% to $37.1 million in 2025.
  • Cash and equivalents fell 41.9% to $41.3 million by end-2025.

Bottom Line

Atossa remains a research-focused company with no commercial products. Its future depends on clinical trial success and new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Steven C. Quay, MD, PhD

Website

www.atossatherapeutics.com

Headquarters

Seattle, WA 98104, US

ATOS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-84.91%

Return on Capital

-94.38%

Return on Assets

-99.20%

Earnings Yield

-1.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.97M

Volume

7

Avg. Volume

154.36K

Financials (TTM)

Gross Profit

-$8.00K

Operating Income

-$39.60M

EBITDA

-$37.63M

Operating Cash Flow

-$33.38M

Capital Expenditure

-$14.00K

Free Cash Flow

-$33.40M

Cash & ST Invst.

$31.72M

Total Debt

$0.00

Atossa Therapeutics Performance Analysis

Atossa Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Atossa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Atossa Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.1920.8%
20232023-12-31USD -3.5812.1%
20242024-12-31USD -3.04-15.1%
20252025-12-31USD -4.0432.8%
Atossa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-25.4%
Q32025-09-30-3.3%
Q42025-12-31-25.7%
Q12026-03-3112.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$4.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$24.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.50M

N/A

Employees

16

N/A

Net Income

-$9.59M

-42.7%

EBITDA

-$9.59M

-42.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$31.72M

-51.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-99.20%

N/A

Return on Invested Capital

-1.30%

N/A

Free Cash Flow

-$9.58M

-60.5%

Operating Cash Flow

-$9.58M

-60.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TVGNTevogen Bio Holdings Inc.
$4.28-2.95%
TILInstil Bio, Inc.
$7.15-0.76%
CLNNClene Inc.
$5.37-2.01%
CGTXCognition Therapeutics, Inc.
$0.94-2.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.07%
AALAmerican Airlines Group
$14.45+0.07%
CLFCleveland-Cliffs
$11.91+0.09%
MARAMara Holdings
$12.57-0.02%

Questions About ATOS

What is the current price of Atossa Therapeutics?

Atossa Therapeutics is trading at $2.34 per share.

What is the 52-week range for Atossa Therapeutics?

Over the past 52 weeks, Atossa Therapeutics has traded between $1.70 and $19.35.

How much debt does Atossa Therapeutics have?

As of the most recent reporting period, Atossa Therapeutics reported total debt of $0.00.

How much cash does Atossa Therapeutics have on hand?

Atossa Therapeutics reported $31.83M in cash and cash equivalents in its most recent financial results.

What is Atossa Therapeutics’s dividend yield?

Atossa Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services